{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:58:15Z","timestamp":1785877095196,"version":"3.56.0"},"reference-count":45,"publisher":"Impact Journals, LLC","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging"],"published-print":{"date-parts":[[2024,6,15]]},"DOI":"10.18632\/aging.205894","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T13:28:04Z","timestamp":1717594084000},"page":"9692-9708","source":"Crossref","is-referenced-by-count":3,"title":["Prognostic and therapeutic roles of SETD2 in cutaneous melanoma"],"prefix":"10.18632","volume":"16","author":[{"given":"Jiani","family":"Xiong","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China"},{"name":"Cancer Bio-immunotherapy Center, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Zhu","sequence":"additional","affiliation":[{"name":"Medical Research Center, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics and Gynecology and Pediatrics, Fujian Medical University, Fuzhou, Fujian, China"},{"name":"NHC Key Laboratory of Technical Evaluation of Fertility Regulation for Non-human Primate, Fujian Maternity and Child Health Hospital, Fuzhou, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunrong","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China"},{"name":"Cancer Bio-immunotherapy Center, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China"},{"name":"Department of Pharmacology, College of Pharmacy, Fujian Medical University, Fuzhou, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhoujie","family":"Ye","sequence":"additional","affiliation":[{"name":"Medical Research Center, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics and Gynecology and Pediatrics, Fujian Medical University, Fuzhou, Fujian, China"},{"name":"NHC Key Laboratory of Technical Evaluation of Fertility Regulation for Non-human Primate, Fujian Maternity and Child Health Hospital, Fuzhou, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuimin","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, QuanZhou Women\u2019s and Children\u2019s Hospital, Quanzhou, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrui","family":"Wang","sequence":"additional","affiliation":[{"name":"Medical Research Center, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics and Gynecology and Pediatrics, Fujian Medical University, Fuzhou, Fujian, China"},{"name":"NHC Key Laboratory of Technical Evaluation of Fertility Regulation for Non-human Primate, Fujian Maternity and Child Health Hospital, Fuzhou, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China"},{"name":"Cancer Bio-immunotherapy Center, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China"},{"name":"College of Chemistry, Fuzhou University, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2024,6,5]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1038\/s41467-023-38265-3","article-title":"Detecting recurrent passenger mutations in melanoma by targeted UV damage sequencing.","volume":"1","author":"Wyrick","year":"2023","journal-title":"Nat Commun"},{"key":"2","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","article-title":"The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors.","volume":"7","author":"Patel","year":"2019","journal-title":"J Immunother Cancer"},{"key":"3","doi-asserted-by":"publisher","first-page":"e006454","DOI":"10.1136\/jitc-2022-006454","article-title":"High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis.","volume":"1","author":"Park","year":"2023","journal-title":"J Immunother Cancer"},{"key":"4","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors.","volume":"2","author":"Lemery","year":"2021","journal-title":"Clin Cancer Res"},{"key":"5","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.","volume":"3","author":"Ferrarotto","year":"2021","journal-title":"Ann Oncol"},{"key":"6","doi-asserted-by":"publisher","first-page":"558","DOI":"10.3390\/cancers13030558","article-title":"PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer.","volume":"1","author":"Brandi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1080\/1744666X.2022.2044796","article-title":"BRAF inhibitors and their immunological effects in malignant melanoma.","volume":"1","author":"Papa","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"8","doi-asserted-by":"publisher","first-page":"9890","DOI":"10.3390\/ijms22189890","article-title":"Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy-Paradoxical ERK Activation and Beyond.","volume":"2","author":"Bros","year":"2021","journal-title":"Int J Mol Sci"},{"key":"9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance.","volume":"1","author":"Engleman","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"10","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12943-020-01290-7","article-title":"The complex relationship between MITF and the immune system: a Melanoma ImmunoTherapy (response) Factor?","volume":"1","author":"Bertolotto","year":"2020","journal-title":"Mol Cancer"},{"key":"11","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).","volume":"3","author":"Leal","year":"2021","journal-title":"J Clin Oncol"},{"key":"12","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.molcel.2004.09.016","article-title":"A protein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington\u2019s disease.","volume":"1","author":"Scherzinger","year":"2004","journal-title":"Mol Cell"},{"key":"13","doi-asserted-by":"publisher","first-page":"102102","DOI":"10.1016\/j.jbc.2022.102102","article-title":"Interplay between H3K36me3, methyltransferase SETD2, and mismatch recognition protein MutS\u03b1 facilitates processing of oxidative DNA damage in human cells.","volume":"29","author":"Li","year":"2022","journal-title":"J Biol Chem"},{"key":"14","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1101\/gad.284323.116","article-title":"Molecular basis for oncohistone H3 recognition by SETD2 methyltransferase.","volume":"3","author":"Li","year":"2016","journal-title":"Genes Dev"},{"key":"15","doi-asserted-by":"publisher","first-page":"15701","DOI":"10.1074\/jbc.M808431200","article-title":"Heterogeneous nuclear ribonucleoprotein L Is a subunit of human KMT3a\/Set2 complex required for H3 Lys-36 trimethylation activity","volume":"28","author":"Reinberg","year":"2009","journal-title":"J Biol Chem"},{"key":"16","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/ng.2894","article-title":"Identification of functional cooperative mutations of SETD2 in human acute leukemia.","volume":"4","author":"Yang","year":"2014","journal-title":"Nat Genet"},{"key":"17","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.cell.2013.03.025","article-title":"The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutS\u03b1.","volume":"15","author":"Li","year":"2013","journal-title":"Cell"},{"key":"18","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1182\/blood.2019001963","article-title":"SETD2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDS.","volume":"13","author":"Liu","year":"2020","journal-title":"Blood"},{"key":"19","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1136\/gutjnl-2015-309482","article-title":"SETD2 histone modifier loss in aggressive GI stromal tumours.","volume":"6","author":"Loh","year":"2016","journal-title":"Gut"},{"key":"20","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1136\/gutjnl-2019-318362","article-title":"Loss of Setd2 promotes Kras-induced acinar-to-ductal metaplasia and epithelia-mesenchymal transition during pancreatic carcinogenesis.","volume":"6","author":"Xiao","year":"2020","journal-title":"Gut"},{"key":"21","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/s41422-018-0015-9","article-title":"Setd2 deficiency impairs hematopoietic stem cell self-renewal and causes malignant transformation.","volume":"2","author":"Huang","year":"2018","journal-title":"Cell Res"},{"key":"22","doi-asserted-by":"publisher","first-page":"e2202937","DOI":"10.1002\/advs.202202937","article-title":"Tumor Cell-Intrinsic SETD2 Deficiency Reprograms Neutrophils to Foster Immune Escape in Pancreatic Tumorigenesis.","volume":"1","author":"Zhao","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"23","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1038\/s41467-018-04329-y","article-title":"MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity.","volume":"9","author":"M\u00fcller","year":"2018","journal-title":"Nat Commun"},{"key":"24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.humpath.2022.12.001","article-title":"Clinical and histopathologic characterization of SETD2-mutated colorectal cancer.","volume":"13","author":"Yang","year":"2023","journal-title":"Hum Pathol"},{"key":"25","doi-asserted-by":"publisher","first-page":"2161194","DOI":"10.1080\/16078454.2022.2161194","article-title":"SETD2 detection may reveal response to induction therapy and survival profile in acute myeloid leukemia patients.","volume":"2","author":"Liu","year":"2023","journal-title":"Hematology"},{"key":"26","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1002\/imt2.36","article-title":"Sangerbox: a comprehensive, interaction-friendly clinical bioinformatics analysis platform.","volume":"1","author":"Song","year":"2022","journal-title":"iMeta"},{"key":"27","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1038\/s41375-019-0456-2","article-title":"SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints.","volume":"3","author":"Wang","year":"2019","journal-title":"Leukemia"},{"key":"28","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1515\/med-2020-0223","article-title":"Circular RNA circ_SETD2 represses breast cancer progression via modulating the miR-155-5p\/SCUBE2 axis.","volume":"1","author":"Zhang","year":"2020","journal-title":"Open Med (Wars)"},{"key":"29","doi-asserted-by":"publisher","first-page":"25189","DOI":"10.18632\/aging.104120","article-title":"Histone methyltransferase SETD2 inhibits tumor growth via suppressing CXCL1-mediated activation of cell cycle in lung adenocarcinoma.","volume":"1","author":"Jiang","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"30","doi-asserted-by":"publisher","first-page":"e1475","DOI":"10.1002\/ctm2.1475","article-title":"Loss of SETD2 aggravates colorectal cancer progression caused by SMAD4 deletion through the RAS\/ERK signalling pathway.","volume":"1","author":"Gao","year":"2023","journal-title":"Clin Transl Med"},{"key":"31","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1038\/leu.2016.134","article-title":"Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia.","volume":"3","author":"Davis","year":"2016","journal-title":"Leukemia"},{"key":"32","doi-asserted-by":"publisher","first-page":"e007678","DOI":"10.1136\/jitc-2023-007678","article-title":"Tumor cell-intrinsic SETD2 inactivation sensitizes cancer cells to immune checkpoint blockade through the NR2F1-STAT1 pathway.","volume":"1","author":"Bi","year":"2023","journal-title":"J Immunother Cancer"},{"key":"33","doi-asserted-by":"publisher","first-page":"216470","DOI":"10.1016\/j.canlet.2023.216470","article-title":"Setd2 deficiency promotes gastric tumorigenesis through inhibiting the SIRT1\/FOXO pathway.","volume":"57","author":"Li","year":"2023","journal-title":"Cancer Lett"},{"key":"34","doi-asserted-by":"publisher","first-page":"842496","DOI":"10.3389\/fonc.2022.842496","article-title":"Melanoma, Melanin, and Melanogenesis: The Yin and Yang Relationship.","volume":"1","author":"Slominski","year":"2022","journal-title":"Front Oncol"},{"key":"35","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2014.06.030","article-title":"The role of melanogenesis in regulation of melanoma behavior: melanogenesis leads to stimulation of HIF-1\u03b1 expression and HIF-dependent attendant pathways.","volume":"56","author":"Seagroves","year":"2014","journal-title":"Arch Biochem Biophys"},{"key":"36","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.tins.2023.01.003","article-title":"How cancer hijacks the body\u2019s homeostasis through the neuroendocrine system.","volume":"4","author":"Slominski","year":"2023","journal-title":"Trends Neurosci"},{"key":"37","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1002\/mc.23614","article-title":"Loss of SETD2-mediated downregulation of intracellular and exosomal miRNA-10b determines MAPK pathway activation and multidrug resistance in renal cancer.","volume":"6","author":"Li","year":"2023","journal-title":"Mol Carcinog"},{"key":"38","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1101\/gr.158253.113","article-title":"Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects.","volume":"2","author":"Davis","year":"2014","journal-title":"Genome Res"},{"key":"39","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41698-021-00193-0","article-title":"Pan-cancer analysis of SETD2 mutation and its association with the efficacy of immunotherapy.","volume":"5","author":"Shen","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"40","doi-asserted-by":"publisher","first-page":"5699","DOI":"10.1038\/onc.2015.24","article-title":"SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair.","volume":"3","author":"Wilson","year":"2015","journal-title":"Oncogene"},{"key":"41","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1056\/NEJMc1508163","article-title":"Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma.","volume":"37","author":"Snyder","year":"2015","journal-title":"N Engl J Med"},{"key":"42","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.1016\/j.molcel.2022.09.007","article-title":"Histone methylation antagonism drives tumor immune evasion in squamous cell carcinomas.","volume":"8","author":"Zhang","year":"2022","journal-title":"Mol Cell"},{"key":"43","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.ccell.2023.03.010","article-title":"Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma.","volume":"4","author":"Salvador","year":"2023","journal-title":"Cancer Cell"},{"key":"44","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12943-022-01651-4","article-title":"The reversion of DNA methylation-induced miRNA silence via biomimetic nanoparticles-mediated gene delivery for efficient lung adenocarcinoma therapy.","volume":"2","author":"Zhang","year":"2022","journal-title":"Mol Cancer"},{"key":"45","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1146\/annurev-pathol-042220-022304","article-title":"DNA Methylation Profiling: An Emerging Paradigm for Cancer Diagnosis.","volume":"1","author":"Aldape","year":"2022","journal-title":"Annu Rev Pathol"}],"container-title":["Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.205894","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T10:51:27Z","timestamp":1718880687000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.205894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,5]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,6,15]]}},"alternative-id":["205894","38843391"],"URL":"https:\/\/doi.org\/10.18632\/aging.205894","relation":{},"ISSN":["1945-4589"],"issn-type":[{"value":"1945-4589","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,5]]}}}